General Committee of Teaching Hospitals and Institutes, Egypt

Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery

Phase 4, Not yet recruiting, 2026, 100 people, 5 Oct 2026, clinicaltrials.gov

Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery

Phase 4, Not yet recruiting, 2026, 100 people, 5 Oct 2026, clinicaltrials.gov

Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain

Phase 4, Not yet recruiting, 2026, 100 people, 5 Oct 2026, clinicaltrials.gov

Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)

Phase 4, Not yet recruiting, 2026, 104 people, 5 Oct 2026, clinicaltrials.gov

Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher

Phase 4, Not yet recruiting, 2026, 100 people, 5 Oct 2026, clinicaltrials.gov

NCT07077525

Collaborator, Phase 4, Completed, 2023, 196 people, 22 Jul 2025, clinicaltrials.gov